RPTX Repare Therapeutics
- 3.800
- -0.120-3.06%
- 3.700
- -0.100-2.63%
Repare Therapeutics News
Capital One Financial Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $21
Capital One Financial analyst Tim Chiang maintains $Repare Therapeutics(RPTX.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a success rate of
Express News | Foundation Medicine: Partnership to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib
Express News | Foundation Medicine: Co Announces Partnership With Repare Therapeutics
Foundation Medicine Announces Partnership With Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib
Foundation Medicine, Inc., today announced that it has formed a collaboration with Repare Therapeutics, a leading clinical-stage precision oncology company, to provide prospective genomic profiling to patients in
Express News | Repare Therapeutics Inc- Repare Expects a Potential Data Readout in Camonsertib Monotherapy Nsclc Expansion in 2025
Express News | Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of Tresr Clinical Trial
H.C. Wainwright Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright analyst Robert Burns maintains $Repare Therapeutics(RPTX.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 24.
Repare Gets FDA Fast Track Status for Ovarian Cancer Drug Combo
Express News | Repare Therapeutics Receives FDA Fast Track Designation For Lunresertib In Combination With Camonsertib For Platinum-Resistant Ovarian Cancer
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination With Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at
Express News | HC Wainwright & Co. Reiterates Buy on Repare Therapeutics, Maintains $10 Price Target
Repare Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 203.03% HC Wainwright & Co. $10 → $10 Reiterates Buy → Buy 03/08/2024 203.03% HC Wainwright & C
Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Repare Therapeutics (RPTX)
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib (RP-6306) in
Repare Therapeutics: A Strong Buy on Robust Financials and Promising Clinical Pipeline
Repare Therapeutics Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates
It's been a good week for Repare Therapeutics Inc. (NASDAQ:RPTX) shareholders, because the company has just released its latest first-quarter results, and the shares gained 8.7% to US$3.64. Reve
Repare Therapeutics Shares Rise 17% After 1Q Earnings, Revenue Beats
By Chris Wack Repare Therapeutics shares were up 17% to $3.85 after the company reported first-quarter earnings that beat analysts' expectations. The company reported quarterly earnings of $13 milli
Repare Therapeutics Shares Are Trading Higher Following Better-than-expected Q1 Financial Results.
Repare Therapeutics Shares Are Trading Higher Following Better-than-expected Q1 Financial Results.
Express News | Repare Therapeutics Shares Are Trading Higher Following Better-than-expected Q1 Financial Results
Analysis
Price Target
No Data
